Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 515
- Registration Number
- NCT00440947
- Locations
- ๐ต๐ท
GSK Investigational Site, San Juan, Puerto Rico
Expanded Access Program for Maraviroc At Multiple Centers
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1047
- Registration Number
- NCT00426660
- Locations
- ๐บ๐ธ
AltaMed Health Services Corporation, Los Angeles, California, United States
๐บ๐ธSynergy Hematology-Oncology Associates, Los Angeles, California, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 100
- Registration Number
- NCT00354653
- Locations
- ๐ฎ๐ท
GSK Clinical Trials Call Center, Tehran, Iran, Islamic Republic of
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 753
- Registration Number
- NCT00296504
- Locations
- ๐ฌ๐ง
GSK Investigational Site, London, United Kingdom
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT00257621
- Locations
- ๐บ๐ธ
GSK Investigational Site, Seattle, Washington, United States
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 130
- Registration Number
- NCT00242879
- Locations
- ๐ฌ๐ง
GSK Investigational Site, London, United Kingdom
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT00242840
- Locations
- ๐ฎ๐น
GSK Investigational Site, Brescia, Lombardia, Italy
Fosamprenavir Expanded Access
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 85
- Registration Number
- NCT00240552
- Locations
- ๐จ๐ญ
GSK Investigational Site, Zurich, Switzerland
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT00197145
- Locations
- ๐ต๐ท
GSK Investigational Site, San Juan, Puerto Rico
GW873140 In Combination With Combivir In HIV Infected Subjects
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 125
- Registration Number
- NCT00104429
- Locations
- ๐ฌ๐ง
GSK Investigational Site, London, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath